Biotech | May 10, 2022
Bora Pharmaceuticals acquires Eden Biologics CDMO assets
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
The new building is expected to be commissioned by 2024. Post the expansion, Nanavati-Max Hospital will be amongst the largest private sector hospital in western India
Subscribe To Our Newsletter & Stay Updated
